Max-Planck – Focus Symposium – Host-directed therapy : New ways to curing infections
November 16th to 17th, 2015
Berlin
The aim of the conference is to bring together pioneers in this emerging research area, discuss their most recent findings and future applications, as well as potential constraints of the approach for medical use. To this end, key scientists in the field as well as experts from the pharmaceutical industries will present their latest results and provide their views on the importance of new treatment strategies.
2015 International HBV Meeting – The Molecular Biology of Hepatitis B Viruses
October 4, 2015 – October 8, 2015
Bad Nauheim, Germany
The International Meeting of the Molecular Biology of Hepatitis B Viruses remains the definitive international meeting that covers all aspects of the biology of hepatitis B and hepatitis D, including biochemistry, molecular biology, traditional virology, immunology, pathogenesis, and carcinogenesis, as well as the latest developments in antiviral therapies against these two viruses.
Pr P. André’s talk : “Reciprocal effect of HBV infection and FXR activation on the expression of FXR controlled genes”.
EASL – The International Liver Congress 2016
13-17 April 2016
Barcelona, Spain
Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research.
ENYO Pharma strengthens its arsenal of hepatitis B potential therapies
Lyon, November 25, 2015 – ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, is announcing that it has obtained a license to a key patent enabling it to use agonists of the farnesoid X receptor (FXR) as hepatitis B treatments.
POXEL and ENYO Pharma Sign License Agreement on POXEL’s FXR Agonists Program
Lyon, France, May 6, 2015 – POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and ENYO Pharma SAS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights regarding therapeutic indications centered on its core expertise.
Latest Press Release 